GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » EBIT

Usana Health Sciences (Usana Health Sciences) EBIT : $101.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences EBIT?

Usana Health Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $27.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $101.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Usana Health Sciences's annualized ROC % for the quarter that ended in Mar. 2024 was 19.30%. Usana Health Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 109.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Usana Health Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 17.67%.


Usana Health Sciences EBIT Historical Data

The historical data trend for Usana Health Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Usana Health Sciences EBIT Chart

Usana Health Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.56 178.46 170.70 108.81 102.72

Usana Health Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.53 26.85 20.57 26.76 27.16

Competitive Comparison of Usana Health Sciences's EBIT

For the Packaged Foods subindustry, Usana Health Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Usana Health Sciences's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Usana Health Sciences's EV-to-EBIT falls into.



Usana Health Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $101.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Usana Health Sciences  (NYSE:USNA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Usana Health Sciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=98.692 * ( 1 - 39% )/( (311.258 + 312.57)/ 2 )
=60.20212/311.914
=19.30 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=632.757 - 22.598 - ( 330.42 - max(0, 118.845 - 417.746+330.42))
=311.258

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Usana Health Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=108.652/( ( (99.814 + max(-30.656, 0)) + (98.186 + max(-18.577, 0)) )/ 2 )
=108.652/( ( 99.814 + 98.186 )/ 2 )
=108.652/99
=109.75 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 61.454 + 18.671) - (22.598 + 13.91 + 74.273)
=-30.656

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 60.87 + 31.864) - (8.266 + 0 + 103.045)
=-18.577

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Usana Health Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=101.346/573.504
=17.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Usana Health Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Usana Health Sciences (Usana Health Sciences) Business Description

Traded in Other Exchanges
Address
3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
Executives
John Turman Fleming director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Gilbert A Fuller officer: CFO and Executive V.P. 55 WANDERWOOD WAY, SANDY UT 84092
Frederic J Winssinger director 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018
David Mulham Mulham officer: Chief Field Development Office 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Paul A. Jones officer: CFO 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Xia Ding director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Daniel A. Macuga officer: Chief Communications Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Jim Brown officer: Chief Production Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Brent Neidig officer: CO & Man. Dir. of China 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
J Scott Nixon director 757 EAST SOUTH TEMPLE, SUITE 150, SALT LAKE CITY UT 84102
Kevin Guest officer: E.V.P. of Marketing 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Joshua Foukas officer: Chief Legal Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
G Doug Iiekking officer: VP of Finance C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Walter Noot officer: Chief Information Officer 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Robert A Sinnott officer: Chief Scientific Officer 400 55 WATER STREET, VANCOUVER A1 V6B1A1

Usana Health Sciences (Usana Health Sciences) Headlines